Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 14.2% Higher

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s share price traded up 14.2% during mid-day trading on Wednesday . The stock traded as high as $3.81 and last traded at $3.77, 1,995,400 shares changed hands during mid-day trading. An increase of 54% from the average session volume of 1,297,427 shares. The stock had previously closed at $3.30.

Several brokerages have recently weighed in on LXRX. Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 16th. ValuEngine raised shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Citigroup cut shares of Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and upped their price target for the stock from $3.00 to $4.00 in a research report on Friday, November 8th. G.Research raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, Gabelli raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a research report on Wednesday, September 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company’s stock. Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $6.45.

The firm’s 50-day moving average price is $3.63 and its two-hundred day moving average price is $3.88. The stock has a market cap of $400.65 million, a PE ratio of -3.31 and a beta of 1.00. The company has a current ratio of 8.11, a quick ratio of 8.01 and a debt-to-equity ratio of 1.42.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.80. Lexicon Pharmaceuticals had a net margin of 49.78% and a return on equity of 2,372.40%. The firm had revenue of $294.45 million during the quarter, compared to analysts’ expectations of $12.00 million. During the same quarter in the prior year, the company earned ($0.26) EPS. The company’s revenue was up 4124.5% compared to the same quarter last year. On average, analysts anticipate that Lexicon Pharmaceuticals, Inc. will post 0.93 earnings per share for the current year.

In other news, Director Christopher J. Sobecki bought 99,249 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The stock was bought at an average price of $2.41 per share, with a total value of $239,190.09. Following the completion of the transaction, the director now directly owns 13,645 shares of the company’s stock, valued at approximately $32,884.45. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher J. Sobecki bought 25,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were purchased at an average cost of $2.55 per share, with a total value of $63,750.00. Following the transaction, the director now directly owns 112,493 shares of the company’s stock, valued at $286,857.15. The disclosure for this purchase can be found here. Insiders bought a total of 178,749 shares of company stock valued at $474,560 in the last ninety days. Corporate insiders own 6.40% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Trexquant Investment LP purchased a new stake in Lexicon Pharmaceuticals during the second quarter valued at approximately $92,000. Commonwealth Equity Services LLC lifted its position in Lexicon Pharmaceuticals by 40.5% during the third quarter. Commonwealth Equity Services LLC now owns 16,461 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 4,746 shares during the last quarter. Voloridge Investment Management LLC purchased a new stake in Lexicon Pharmaceuticals during the second quarter valued at approximately $105,000. Quantitative Systematic Strategies LLC lifted its position in Lexicon Pharmaceuticals by 67.2% during the second quarter. Quantitative Systematic Strategies LLC now owns 20,648 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 8,302 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Lexicon Pharmaceuticals by 77.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 61,642 shares of the biopharmaceutical company’s stock valued at $388,000 after acquiring an additional 26,900 shares during the last quarter. 96.27% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Read More: What causes a recession?

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.